Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

• Published in: In vivo (Athens) Vol. 35; no. 5; pp. 2981 - 2990
• Main Authors: KOPECKY, JINDRICH, KUBECEK, ONDREJ, BUCHLER, TOMAS, MELICHAR, BOHUSLAV, POPRACH, ALEXANDR, ZEMANOVA, MILADA, KATOLICKA, JANA, KISS, IGOR, HAJEK, JAROSLAV, STUDENTOVA, HANA, SPISAROVA, MARTINA
• Format: Journal Article
• Language: English
• Published: International Institute of Anticancer Research 01.09.2021

BACKGROUND/AIMImmunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in cl...